3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
5
Tumor-Agnostic
3
Head & Neck
2
Genitourinary
2
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Conditions
Ovarian Neoplasms
4
Endometrial Neoplasms
4
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Treatment for Metastatic or Locally Advanced Cervical Cancer
1
Recurrence
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Colonic Neoplasms
1
Advanced Endometrial Cancer
1
Interventions
pembrolizumab
23
Paclitaxel
14
Cyclophosphamide
13
Carboplatin
12
Specimen Handling
10
Magnetic Resonance Spectroscopy
10
Biopsy
9
fludarabine
8
Nivolumab
7
Leucovorin
7
Gemcitabine
7
Fluorouracil
7
Doxorubicin
7
aldesleukin
6
Oxaliplatin
6
Cisplatin
6
liposomal doxorubicin
5
Topotecan
5
Taxes
5
Irinotecan
5
Interleukin-2
5
olaparib
4
atezolizumab
4
Hyperthermic Intraperitoneal Chemotherapy
4
Drug Therapy
4
seribantumab
3
fludarabine phosphate
3
durvalumab
3
dostarlimab
3
dehydroftorafur
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
NVP-BKM120
×
Gynecologic
×
Clear all
NCT01397877
2023-09-06
ENDOPIK
ARCAGY/ GINECO GROUP
Phase 2
Completed
24 enrolled